The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.
The company will provide oncology specimens and associated clinical data to the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium.
5AM Solutions will develop software that will allow Asterand to electronically link multiple biorepositories and identify, annotate, and distribute biospecimen data internally and with collaborators.
The contract to supply biospecimens for the Cancer Genome Atlas project could reach a total value of $24 million.
BioSeek will apply its BioMap predictive human disease models to screen Amylin's library.
The Japanese pharmaceutical developer has licensed the BioMap platform for drug toxicology research projects.
BioSeek will use its BioMap system to conduct screening for Ono Pharmaceuticals in its compound studies.
Affymetrix, Febit, Asterand, ImaGenes
BMS will continue to use Asterand's tissue-based drug-discovery products and services for up to three years.
The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.